PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Rising Growth Potential for Disease Modification Drugs in U.S Alzheimer’s Disease Medication Market - New analysis from Frost & Sullivan, U.S. Alzheimer’s Disease Medication Markets, finds that the market earned revenues of $2.41 billion in 2006 and estimates this to exceed $4.00 billion in 2013
Rising Growth Potential for Disease Modification Drugs in U.S Alzheimer’s Disease Medication Market

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/06/26 - New analysis from Frost & Sullivan, U.S. Alzheimer’s Disease Medication Markets, finds that the market earned revenues of $2.41 billion in 2006 and estimates this to exceed $4.00 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Alzheimer’s disease (AD) medication market is set to gravitate toward therapies capable of arresting or slowing the disease progression. As the currently marketed drugs provide only symptomatic alleviation, the AD medication market offers ample opportunities for growth, in particular for drugs that can modify the course of the disease.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Alzheimer’s Disease Medication Markets, finds that the market earned revenues of $2.41 billion in 2006 and estimates this to exceed $4.00 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Alzheimer’s Disease Medication Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

“The potential of this unmet needs market has attracted considerable attention from drug developers,” notes Frost & Sullivan Research Analyst Adriana Rusu. “The first wave of disease modifying drugs is likely to reach the market within the next couple of years, and in combination with symptomatic drugs, could enhance treatment options in this growing market.”

Demand for AD medication is set to increase with the rising disease prevalence resulting from the growing number of the baby-boomer population that will reach the age of 65 within the next several years. Simultaneously, an increased level of awareness about Alzheimer's, coupled with improved diagnostic techniques, are likely to expand the patient base and fuel market growth. Moreover, increased research and development activity is expected to expand the treatment options in the near future, and consequently the overall AD medication market.

Presently, due to patent protection, only branded drugs are available to treat Alzheimer’s. However, the competitive landscape is expected to soon change as their patent expiration dates are nearing. With the possibility of generics reaching the market by 2009, competition in the AD medication market is likely to intensify. Consequently, the availability of less expensive generics is expected to temporarily restrain market growth, before the new disease-modifying drugs are able to establish a strong market presence.

Manufacturers of existing drugs, which are facing pending generic erosion, can distinguish their products in particular through new drug delivery methods and formulations. Given the special needs of the AD patient population, such strategies are most likely to appeal to end users and have a market impact.

However, the developers of new drugs are facing different challenges. For drugs in development, time-to-market is critical to seize the opportunity provided by the high needs of this market. “Designing and conducting effective clinical trials that could ensure successful outcomes and compelling results may accelerate the time-to-market and aid in establishing a solid competitive advantage,” concludes Rusu.

U.S. Alzheimer’s Disease Medication Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Service Program, which includes research services in the following markets: U.S. Generic Pharmaceuticals, U.S. Multiple Myeloma, and U.S. COPD: Therapeutic Overview and Patient Outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Rising Growth Potential for Disease Modification Drugs in U.S Alzheimer’s Disease Medication Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino@[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)